Randomized Comparison of Upstream Tirofiban Versus Downstream High Bolus Dose Tirofiban or Abciximab on Tissue-Level Perfusion and Troponin Release in High-Risk Acute Coronary Syndromes Treated With Percutaneous Coronary Interventions
The EVEREST Trial
Leonardo Bolognese, MD, FESC*,
Giovanni Falsini, MD,
Francesco Liistro, MD,
Paolo Angioli, MD,
Kenneth Ducci, MD,
Tamara Taddei, MD,
Roberto Tarducci, MD,
Franco Cosmi, MD,
Silvia Baldassarre, MD and
Antonio Burali, MD
Azienda Ospedaliera Arezzo, Arezzo, Italy
View larger version (12K):
[in a new window]
|
Figure 1 Rate of Thrombolysis In Myocardial Infarction myocardial perfusion grade (TMPG) 0/1 flow stratified by glycoprotein IIb/IIIa inhibitor treatment pre-percutaneous coronary intervention (PCI) (A) and post-PCI (B). p = 0.0009 by Fisher exact test upstream tirofiban vs. high-dose bolus (HDB) vs. abciximab before PCI. p = 0.015 by Fisher exact test upstream tirofiban vs. HDB vs. abciximab after PCI.
|
|
View larger version (12K):
[in a new window]
|
Figure 2 (A) Myocardial contrast echocardiography score index (MCSEI) as a semiquantitative index of impaired tissue perfusion in the three groups of patients. p < 0.05 by analysis of variance (ANOVA) upstream tirofiban versus high-dose bolus (HDB) versus abciximab. (B) Patients perfused by myocardial contrast echocardiography (MCE) among the three therapeutic regimen groups. p = 0.04 by ANOVA upstream tirofiban vs. HDB vs. abciximab.
|
|
|
